Cart
sales@molnova.com
RO3244794
CAS No. 361457-01-4
RO3244794( —— )
Catalog No. M36279 CAS No. 361457-01-4
RO3244794 is a selective prostacyclin (IP) receptor antagonist that can be used to study liver injury.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 406 | In Stock |
|
| 10MG | 509 | In Stock |
|
| 25MG | 752 | In Stock |
|
| 50MG | 986 | In Stock |
|
| 100MG | 1330 | In Stock |
|
| 200MG | 1795 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRO3244794
-
NoteResearch use only, not for human use.
-
Brief DescriptionRO3244794 is a selective prostacyclin (IP) receptor antagonist that can be used to study liver injury.
-
DescriptionRO3244794 is a selective prostacyclin (IP) receptor antagonist that can be used to study liver injury.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorProstaglandin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number361457-01-4
-
Formula Weight451.42
-
Molecular FormulaC25H19F2NO5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(OC(N[C@H](CC1=CC=C(F)C=C1)C(O)=O)=O)C2=CC=3C(O2)=CC=C(C3)C4=CC=C(F)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
AH 6809
AH 6809 is an antagonist of EP and DP receptor(with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively).
-
Furprofen
Furprofen is a non-steroidal anti-inflammatory agent that inhibits prostate (PGE) synthesis and is used in the study of rheumatoid arthritis and osteoarthritis.
-
Carboprost trometham...
Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin F2α and it can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery.Carboprost tromethamine has been accounted for to be 84-96% successful in the treatment of persistent hemorrhage because of uterine atony.
